Among the 129 Swiss AD patients, there were 5 CYP3A variants: CYP3A4*1B (rs2740574), CYP3A4 (rs4646437), CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746), and CYP3A7*1C (−262T > A and −270T > G), and these variants did not affect the pharmacokinetics of DNP in vivo (Noetzli et al., 2014). The gene discussed is CYP3A5; the disease is Alzheimer disease.